Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on Equity

Seres Therapeutics (MCRB) EBT Margin (2016 - 2025)

Seres Therapeutics' EBT Margin history spans 10 years, with the latest figure at 6227.64% for Q3 2025.

  • For Q3 2025, EBT Margin changed N/A year-over-year to 6227.64%; the TTM value through Sep 2025 reached 10381.11%, up 32436264.0%, while the annual FY2023 figure was 150.61%, 241499.0% up from the prior year.
  • EBT Margin for Q3 2025 was 6227.64% at Seres Therapeutics, down from 4495.31% in the prior quarter.
  • Across five years, EBT Margin topped out at 53.86% in Q3 2021 and bottomed at 194795.31% in Q4 2023.
  • The 5-year median for EBT Margin is 2755.39% (2022), against an average of 17504.43%.
  • The largest annual shift saw EBT Margin plummeted -19456998bps in 2023 before it skyrocketed 19030001bps in 2024.
  • A 5-year view of EBT Margin shows it stood at 688.06% in 2021, then skyrocketed by 67bps to 225.33% in 2022, then tumbled by -86348bps to 194795.31% in 2023, then skyrocketed by 98bps to 4495.31% in 2024, then crashed by -39bps to 6227.64% in 2025.
  • Per Business Quant, the three most recent readings for MCRB's EBT Margin are 6227.64% (Q3 2025), 4495.31% (Q4 2024), and 194795.31% (Q4 2023).